In July 2023, the Lobular Breast Cancer Alliance (LBCA) welcomed Fresia Pareja, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Pareja is an assistant attending in the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center. She currently works as a practicing breast pathologist and physician-scientist.
Dr. Pareja is especially passionate about the molecular characterization of special histological subtypes of breast cancer, such as invasive lobular carcinoma (ILC). She is interested in the integration of genomics, pathology, and artificial intelligence for the development of diagnostic tools for lobular breast cancer and the discovery of novel biology underpinning it.
LBCA also recognizes and thanks Dr. Jorge S. Reis-Filho from Memorial Sloan Kettering Cancer Center as he steps down from the SAB. Dr. Reis-Filho has been a significant contributor to LBCA’s work for more than three years.
LBCA’s SAB members are an internationally-renowned group of clinicians and scientists with significant experience studying ILC. They are committed to LBCA’s mission, vision, and goals and are a critical resource for LBCA helping us ensure that all information developed and shared is current, relevant, and accurate.
SAB members help provide strategic guidance and assist with the implementation of LBCA’s planned research advocacy, ILC education, and ILC research grantmaking activities. They work with the LBCA Patient Advocate Advisory Board to assist LBCA in identifying priority areas for ILC research, and they work in collaboration with other scientists and advocates so that we can effectively and collectively advance the most important research efforts in those areas.